Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2020 06:00 ET | Source: Mesoblast Limited

Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the investigator-initiated...
February 03, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA

NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has submitted its...
January 15, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco

NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported that the United States...
January 02, 2020 06:00 ET | Source: Mesoblast Limited

Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L

MELBOURNE, Australia and NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced that the...
December 18, 2019 06:00 ET | Source: Mesoblast Limited

Data Monitoring Committee Completes Final Scheduled Review of Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) announced today that the independent Data Monitoring Committee (DMC) overseeing the Phase 3 trial of Revascor...
December 17, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion

NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number...
November 25, 2019 16:52 ET | Source: Mesoblast Limited

Mesoblast Finanical Results for the Quarter Ended September 30, 2019

MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended...
November 21, 2019 16:29 ET | Source: Mesoblast Limited

Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019

NEW YORK and MELBOURNE, Australia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst...
October 16, 2019 18:17 ET | Source: Mesoblast Limited

Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy

MELBOURNE, Australia and NEW YORK and BASEL, Switzerland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast (ASX:MSB; Nasdaq:MESO) and Lonza (SWX: LONN) announced today that they have entered into an...
October 03, 2019 07:59 ET | Source: Mesoblast Limited

Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a...